220 related articles for article (PubMed ID: 38311719)
21. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Akizawa T; Otsuka T; Reusch M; Ueno M
Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
[TBL] [Abstract][Full Text] [Related]
22. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Akizawa T; Ueno M; Shiga T; Reusch M
Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
[TBL] [Abstract][Full Text] [Related]
23. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
[TBL] [Abstract][Full Text] [Related]
24. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis.
Zheng Q; Zhang P; Yang H; Geng Y; Tang J; Kang Y; Qi A; Li S
Heliyon; 2023 Apr; 9(4):e15310. PubMed ID: 37123954
[TBL] [Abstract][Full Text] [Related]
25. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
Liu J; Li S; Yang F; Li T; Li R; Waheed Y; Meng C; Li S; Liu K; Tong Y; Xu H; Tian C; Zhou X
Korean J Intern Med; 2024 May; 39(3):488-500. PubMed ID: 38649158
[TBL] [Abstract][Full Text] [Related]
26. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
27. Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
Mata Lorenzo M; Ali M; Mealing S; Moss J
J Med Econ; 2023; 26(1):1250-1260. PubMed ID: 37752891
[TBL] [Abstract][Full Text] [Related]
28. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
30. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
[TBL] [Abstract][Full Text] [Related]
31. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
Mima A; Horii Y
In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
[TBL] [Abstract][Full Text] [Related]
34. Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
[TBL] [Abstract][Full Text] [Related]
35. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
Song J; Chen X; Zhou L; Yu W; Liu H; Yuan F
J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
[TBL] [Abstract][Full Text] [Related]
37. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
[TBL] [Abstract][Full Text] [Related]
38. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
[TBL] [Abstract][Full Text] [Related]
39. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
40. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]